Robert Driscoll
Wedbush | Healthcare
Robert Driscoll is an analyst from Wedbush specializing in the Healthcare sector. Ranked #816 out of 4369 analysts, they have issued 15 stock ratings with a success rate of 81.96% and an average return of 31.00%.
With 15 ratings to date, Robert Driscoll is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 81.96% and an average return of 31.00%, highlighting promising potential as their track record develops further.
Recent Ratings Analysis
REPL
BuyOct 20, 2025
Target
$18.00
Current
$8.10
Performance
-9.50%
Robert Driscoll rated REPL as Outperform on Oct 20, 2025, setting a price target of 18. The stock has underperformed, dropping 9.50% despite the bullish target of 18.
CRBP
BuyOct 20, 2025
Target
$38.00
Current
$19.36
Performance
5.91%
On Oct 20, 2025, CRBP was given a Outperform rating by Robert Driscoll, with a target price of 38. The stock rallied 5.91% after the rating, narrowing the gap to the target of 38 and validating the bullish stance.
RVMD
BuyOct 17, 2025
Target
$77.00
Current
$53.49
Performance
-1.13%
RVMD received a Outperform rating from Robert Driscoll on Oct 17, 2025, aiming for 77. Price action was muted, as shares hovered around 53.49 despite the bullish outlook.
CBIO
BuyJul 14, 2025
Target
$27.00
Current
$12.65
Performance
-1.17%
On Jul 14, 2025, Robert Driscoll published a Outperform outlook on CBIO, with a target of 27. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 12.65.
KURA
BuyJun 20, 2025
Target
$36.00
Current
$9.58
Performance
63.76%
Robert Driscoll on Jun 20, 2025 assigned KURA a Outperform rating, with a price target of 36. The Buy call aligned well with market performance, producing a gain of 63.76%.
ZNTL
HoldMar 28, 2025
Target
$4.00
Current
$1.64
Performance
-9.39%
On Mar 28, 2025, Robert Driscoll reaffirmed ZNTL with a Neutral rating, targeting 4. The Hold stance reflected market caution that was later justified.
GLUE
BuyMar 21, 2025
Target
$17.00
Current
$9.59
Performance
65.34%
GLUE was rated Outperform by Robert Driscoll on Mar 21, 2025, with a price objective of 17. A bullish response from the market helped close the gap of 7.41 to the target.
HOWL
BuyMar 12, 2025
Target
$8.00
Current
$1.61
Performance
30.89%
On Mar 12, 2025, Robert Driscoll initiated coverage on HOWL with a Outperform rating and target of 8. The stock’s climb of 30.89% since the call highlights the foresight in the rating.
ARVN
HoldMar 12, 2025
Target
$12.00
Current
$9.66
Performance
6.98%
Robert Driscoll issued a Neutral recommendation for ARVN on Mar 12, 2025, price target set at 12. A neutral call gave way to stronger-than-expected performance, closing in on 12.
DAWN
BuyFeb 26, 2025
Target
$32.00
Current
$7.51
Performance
-23.91%
On Feb 26, 2025, DAWN was evaluated by Robert Driscoll, who gave a Outperform rating and target of 32. Investors saw limited payoff as shares fell short of the 32 target.
IDYA
BuyDec 17, 2024
Target
$52.00
Current
$29.20
Performance
10.90%
Robert Driscoll rated IDYA as Outperform on Dec 17, 2024, setting a price target of 52. The call has proven timely, with shares rising 10.90% toward the price target of 52.
BDTX
BuyOct 08, 2024
Target
$16.00
Current
$3.96
Performance
11.24%
On Oct 08, 2024, BDTX was given a Outperform rating by Robert Driscoll, with a target price of 16. The stock rallied 11.24% after the rating, narrowing the gap to the target of 16 and validating the bullish stance.
RCUS
BuyOct 03, 2024
Target
$30.00
Current
$18.05
Performance
17.90%
RCUS received a Outperform rating from Robert Driscoll on Oct 03, 2024, aiming for 30. Momentum has favored the Buy call, with shares climbing from 18.05 to 18.05, rewarding those who trusted the recommendation.
IGMS
BuyOct 01, 2024
Target
$22.00
Current
$1.27
Performance
-91.24%
On Oct 01, 2024, Robert Driscoll published a Outperform outlook on IGMS, with a target of 22. Market action contradicted the Buy thesis, as shares slipped to 1.27.
ACET
BuySep 20, 2024
Target
$5.00
Current
$0.92
Performance
-39.75%
Robert Driscoll on Sep 20, 2024 assigned ACET a Outperform rating, with a price target of 5. The call has struggled to gain traction, with shares losing 39.75%.
CGEM
BuySep 18, 2024
Target
$36.00
Current
$8.48
Performance
-50.78%
On Sep 18, 2024, Robert Driscoll reaffirmed CGEM with a Outperform rating, targeting 36. Shares slid 50.78% despite the recommendation, highlighting downside risks.
TYRA
BuyJul 03, 2024
Target
$28.00
Current
$14.71
Performance
-13.32%
TYRA was rated Outperform by Robert Driscoll on Jul 03, 2024, with a price objective of 28. This case shows how bullish projections can fail, with the stock now below 14.71.
CTMX
BuyMay 09, 2024
Target
$8.00
Current
$3.62
Performance
77.21%
On May 09, 2024, Robert Driscoll initiated coverage on CTMX with a Outperform rating and target of 8. The stock’s climb of 77.21% since the call highlights the foresight in the rating.
JANX
BuyMay 08, 2024
Target
$74.00
Current
$26.83
Performance
-51.54%
Robert Driscoll issued a Outperform recommendation for JANX on May 08, 2024, price target set at 74. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.
ELEV
BuyMay 03, 2024
Target
$8.00
Current
$0.36
Performance
-90.14%
On May 03, 2024, ELEV was evaluated by Robert Driscoll, who gave a Outperform rating and target of 8. Investors saw limited payoff as shares fell short of the 8 target.
OMGA
BuyJan 04, 2024
Target
$12.00
Current
$0.14
Performance
-97.32%
Robert Driscoll rated OMGA as Outperform on Jan 04, 2024, setting a price target of 12. The stock has underperformed, dropping 97.32% despite the bullish target of 12.